Charles River Laboratories (CRL) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Market environment and customer sentiment

• Pharma saw strong growth last year, but demand deteriorated abruptly this year, with infrastructure and portfolio reductions across most companies except those making GLP-1 drugs.

• Biotech funding remains volatile and closely tied to interest rates and capital market access, with improvement slower than anticipated.

• Cautious sentiment prevails, driven more by psychology and fear of capital shortages than by current financials.

• Significant pent-up demand exists, with many promising drugs paused and IND filings delayed.

• The company often acts as an early indicator for broader industry trends due to its extensive client base.

Segment performance and operational trends

• Safety Assessment backlog has normalized from 18+ months to 9–12 months, with more rational booking and real studies.

• Pricing pressure is increasing, with studies now booked at lower price points, creating a headwind for 2025.

• Margins in DSA are under pressure, but ongoing cost streamlining and digitalization are expected to improve efficiency over time.

• CDMO business is growing, especially in biologics, with strong client interest in cell and gene therapy manufacturing.

• Microbial Solutions and Biologic Safety Testing are performing well, with strong margins and technological advantages.

Competitive landscape and pricing

• Main competitors are much smaller and compete primarily on price, lacking scientific depth and service breadth.

• Selective and strategic discounting is used to gain or protect share, but pricing power is expected to return as demand recovers.

• Price stabilization is not expected until demand strengthens, with 2025 likely starting with a pricing headwind.